Locate family members with the last name MATIAS-BARRIOS.

Victor M. Matias-Barrios is an academic who published a paper in 2021-02-01 entitled Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics. The paper was published in a journal entitled Frontiers in Oncology.

VICTOR-M. MATIAS-BARRIOS is an academic who published a paper in 2021 entitled Optimization of New Catalytic Topoisomerase II Inhibitors as an Anti-Cancer Therapy. VICTOR-M. MATIAS-BARRIOS published this work as part of a team: Matias-Barrios, Victor M.. Here is a description of this work: Cli,,ically used topoisomerase II (TOP2) inhibitors are poison inhibitors that induce DNA damage to cause cancer cell death. However, they can also destroy benign cells and thereby show serious side effects, including cardiotoxicity and drug-induced secondary malignancy. New TOP2 inhibitors with a different mechanism of action (MOA), such as catalytic TOP2 inhibitors, are needed to more effectively control tumor growth. We have applied computer-aided drug design to develop a new group of small molecule inhibitors that are derivatives of our previously identified lead compound T60. Particularly, the compound T638 has shown improved solubility and microsomal stability. It is a catalytic TOP2 inhibitor that potently suppresses TOP2 activity. T638 has a novel MOA by which it binds TOP2 proteins and blocks TOP2â€"DNA.

VICTOR-MANUEL MATIAS BARRIOS is an academic who published a paper in 2021 entitled New catalytic topoisomerase II inhibitors discovered for anticancer therapeutics. VICTOR-MANUEL MATIAS BARRIOS published this work as part of a team: Matias Barrios, Victor Manuel. Here is a description of this work: Topoisomerase II (TOP2) is a ubiquitous enzyme in human cells that regulates DNA topology and chromatid separation, which is critical for cells to grow and survive. Popular chemotherapeutics (such as doxorubicin and etoposide) are TOP2 poison inhibitors that induce DNA double-stranded breaks, thereby cytotoxicity to initiate cancer cell death. However, they have significant side effects such as secondary malignancy and cardiotoxicity. TOP2 catalytic inhibitors, on the other hand, cause minimal DNA disruption, have low cytotoxicity, and are efficient at inhibiting cancer cell proliferation. They are sought after as potential anticancer treatments. The development of modern TOP2 catalytic inhibitors is discussed in this thesis. We used a computer-aided drug discovery (CADD) campaign to screen over 6 million molecules from the ZINC15 d.